In a news release, the companies said Bristol-Myers will pay $31.00 a share in cash for San Diego-based Amylin.
That adds up to about $5.3 billion.
Including Amylin's net debt and a payment obligation to Eli Lilly & Co. (LLY), however, the deal's total value rises to about $7 billion, the companies said.The purchase price offers a 9.9% premium of to Amylin's closing share price Friday of $28.20. The boards of Bristol-Myers and Amylin have approved the transaction. In addition, following the consummation of the deal, New York-based Bristol-Myers plans expand its diabetes partnership with AstraZeneca PLC (AZN - Get Report). The companies will collaborate on developing and marketing Amylin's portfolio of drugs. AstraZeneca will pay Bristol-Myers Squibb approximately $3.4 billion in cash, and the two partners will split profits and losses from the collaboration. Shares of Bristol-Myers Squibb closed Friday up 87 cents at $35.95. Shares of AstraZeneca ended the session up 36 cents at $44.75.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts